I-Mab — Investor Relations & Filings

I-Mab is a global biotechnology company focused on the discovery, development, and commercialization of innovative biologics for the treatment of cancer. The company's core focus is on immuno-oncology, advancing a pipeline of differentiated therapies. Its portfolio includes several clinical-stage assets with an emphasis on bispecific antibodies. Key candidates in development include givastomig, a Claudin 18.2 x 4-1BB bispecific antibody for gastrointestinal cancers, and ragistomig, a PD-L1 x 4-1BB bispecific antibody for patients with advanced solid tumors, particularly those refractory to checkpoint inhibitors. The pipeline also features uliledlimab, a CD73 antibody.